Systemic infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Have a chronic or active infection that requires systemic antibiotics, antifungal or antiviral treatment
Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Recent or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment within  weeks prior to the start of study drug
Concomitant therapy that includes other chemotherapy that is or may be active against AML except for prophylaxis and/or treatment of opportunistic or other infection with antibiotics, antifungals and/or antiviral agents.
Active clinically serious infections requiring antibiotics, antiviral or antifungal agents; participants must be off these agents for at least  days prior to the first dose of the study drug
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C
Active infection requiring antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patients ability to tolerate therapy
Any ongoing infection whether receiving or not receiving antibiotics or have received intravenous antibiotics, antiviral, or antifungal agents within  weeks prior to the start of the study drug.
Acute active infection requiring intravenous antibiotics, antiviral (except antiviral directed at hepatitis B), or antifungal agents within  days of first dose
Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments
Acute infection requiring intravenous antibiotics, antiviral or antifungal agents during the  days prior to first dose of rucaparib
History of chronic or recurrent infections that require continual use of antiviral, antifungal, or antibacterial agents.
Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments
Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines or a recent infection requiring systemic treatment that was completed ? days before the first dose of study drug.
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Active infection requiring IV antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patients ability to tolerate therapy
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment as such, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
Patients with an active infection that requires systemic antibiotics, antiviral, or antifungal treatments
Chronic or current infectious disease requiring systemic antibiotics, antifungal (excluding antifungals given for nail-beds infections), or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Acute active infection requiring systemic antibiotics, antiviral (except antiviral directed at hepatitis B) or antifungal agents within  days of first dose
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at hepatitis B) or antifungal agents within  days prior to randomization.
Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis C, and known Human Immunodeficiency Virus (HIV) disease. All HIV-positive subjects are excluded from this study, regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining disease and/or are on antiviral therapy.
Chronic or currently active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment including, but not limited to: chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis C, and known HIV disease. All Human Immunodeficient virus (HIV)-positive subjects are excluded from this study, regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining disease and/or are on antiviral therapy.
Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments
Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis C, and known HIV disease. All HIV-positive patients are excluded from this study, regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining disease and/or are on antiviral therapy. Prophylactic antiviral and/or antibacterial antibiotics to prevent recurrence of previous infections are permitted.
Have a chronic or active infection that requires systemic antibiotics, antifungal or antiviral treatment
Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment, except concomitant antiviral systemic therapy for chronic hepatitis B or C.
